# Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

> **NCT00040651** · PHASE1 · TERMINATED · sponsor: **National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)** · enrollment: 15 (—)

## Conditions studied

- Scleroderma
- Systemic Sclerosis

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Thymoglobulin
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Self bone marrow transplant

## Key facts

- **NCT ID:** NCT00040651
- **Lead sponsor:** National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-07
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 15 (—)
- **Last updated:** 2007-12-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00040651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00040651, "Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00040651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*